Results from Part 1 Safety Run-in Period of a 2-part, Phase 2, Multicenter, Open-label, Proof-of-Concept Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of VP-315 in Subjects with Basal Cell Carcinoma

Main Article Content

Neal Bhatia, MD
Therapeutics Clinical Research, San Diego, CA

Jonathon Kantor, MD
Florida Center for Dermatology, St. Augustine, FL

Lawrence Green, MD
Dept. of Dermatology, George Washington University School of Medicine, Washington DC

Jonathon Weiss, MD
Georgia Dermatology Partners and Gwinnett Clinical Research Center Inc., Snellville, GA

Cynthia Wilson, RN, BSN
Verrica Pharmaceuticals Inc., West Chester, PA

Susan Cutler, DMD
Verrica Pharmaceuticals Inc., West Chester, PA

Jayson Rieger, PhD, MBA
PBM Capital Group, Charlottesville, VA

David K. Glover, ME, PhD
PBM Capital Group, Charlottesville, VA

Pamela Rumney, RN, CCRC
Verrica Pharmaceuticals Inc., West Chester, PA

Gary Goldenberg, MD
Verrica Pharmaceuticals Inc., West Chester, PA, Department of Dermatology, Icahn School of Medicine at Mount Sinai Hospital, NY, NY.

Keywords

Basal Cell Carcinoma

Abstract



References

1. Sveinbjørnsson, Baldur et al. “LTX-315: a first-in-class oncolytic peptide that reprograms the tumor microenvironment.” Future Medicinal Chemistry 9 12 (2017): 1339-1344.

2. Eike LM, Yang N, Rekdal Ø, Sveinbjørnsson B. The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells. Oncotarget. 2015 Oct 27;6(33):34910-23.

Article Sidebar

PDF
Published
Nov 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.260

Article Details

How to Cite
Bhatia, N. ., Kantor, J. ., Green, L. ., Weiss, J. ., Willson, C., Cutler, S., Rieger, J., Glover, D. K., Rumney, P., & Goldenberg, G. (2023). Results from Part 1 Safety Run-in Period of a 2-part, Phase 2, Multicenter, Open-label, Proof-of-Concept Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of VP-315 in Subjects with Basal Cell Carcinoma. SKIN The Journal of Cutaneous Medicine, 7(6), s260. https://doi.org/10.25251/skin.7.supp.260
Issue
Vol. 7 No. 6 (2023): November 2023 Issue
Section
Skin Cancer
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Similar Articles

1 2 3 4 5 > >> 

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 > >>